Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication of copy number change in advanced prostate cancer, which defines a wide spectrum of disease from high-risk localised to metastatic, is unknown.
We performed copy number profiling on 688 tumour regions from 300 patients, who presented with advanced prostate cancer prior to the start of long-term androgen deprivation therapy (ADT), in the control arm of the prospective randomised STAMPEDE trial. Patients were categorised into metastatic states as follows; high-risk non-metastatic with or without local lymph node involvement, or metastatic low/high volume. We followed up patients for a median of 7 years. Univariable and multivariable Cox survival models were fitted to estimate the association between the burden of copy number alteration as a continuous variable and the hazard of death or disease progression.
The burden of copy number alterations positively associated with radiologically evident distant metastases at diagnosis (P=0.00006) and showed a non-linear relationship with clinical outcome on univariable and multivariable analysis, characterised by a sharp increase in the relative risk of progression (P=0.003) and death (P=0.045) for each unit increase, stabilising into more modest increases with higher copy number burdens. This association between copy number burden and outcome was similar in each metastatic state. Copy number loss occurred significantly more frequently than gain at the lowest copy number burden quartile (q=4.1 × 10-6). Loss of segments in chromosome 5q21-22 and gains at 8q21-24, respectively including CHD1 and cMYC occurred more frequently in cases with higher copy number alteration (for either region: Kolmogorov-Smirnov distance, 0.5; adjusted P<0.0001). Copy number alterations showed variability across tumour regions in the same prostate. This variance associated with increased risk of distant metastases (Kruskal-Wallis test P=0.037).
Copy number alteration in advanced prostate cancer associates with increased risk of metastases at diagnosis. Accumulation of a limited number of copy number alterations associates with most of the increased risk of disease progression and death. The increased likelihood of involvement of specific segments in high copy number alteration burden cancers may suggest an order underlying the accumulation of copy number changes.
ClinicalTrials.gov NCT00268476 , registered on December 22, 2005. EudraCT 2004-000193-31 , registered on October 4, 2004.
Genome medicine. 2022 Sep 05*** epublish ***
Emily Grist, Stefanie Friedrich, Christopher Brawley, Larissa Mendes, Marina Parry, Adnan Ali, Aine Haran, Alex Hoyle, Claire Gilson, Sharanpreet Lall, Leila Zakka, Carla Bautista, Alex Landless, Karolina Nowakowska, Anna Wingate, Daniel Wetterskog, A M Mahedi Hasan, Nafisah B Akato, Malissa Richmond, Sofeya Ishaq, Nik Matthews, Anis A Hamid, Christopher J Sweeney, Matthew R Sydes, Daniel M Berney, Stefano Lise, STAMPEDE investigators , Mahesh K B Parmar, Noel W Clarke, Nicholas D James, Paolo Cremaschi, Louise C Brown, Gerhardt Attard
Cancer Institute, University College London, London, UK., MRC Clinical Trials Unit at University College London, London, UK., GU Cancer Research/FASTMAN Group, Manchester Cancer Institute, Manchester, UK., The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK., The Institute of Cancer Research, London, UK., Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Barts Cancer Institute, Queen Mary University of London, London, UK., The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK., Cancer Institute, University College London, London, UK. .